Clinical calculators
The arithmetic done on phones between patients, without the adverts: body surface area, carboplatin AUC dosing, creatinine clearance, neutrophil count and grade, albumin-corrected calcium, RECIST 1.1 percentage change and category, cumulative anthracycline exposure and dose banding. Every formula is cited; every result has a copy button; nothing you enter leaves the page.
Body surface area and BSA dose
Mosteller: √(height × weight / 3600). Du Bois: 0.007184 × W^0.425 × H^0.725
Source: Mosteller, NEJM 1987; Du Bois & Du Bois, Arch Intern Med 1916
Creatinine clearance and carboplatin (Calvert)
CrCl = (140 − age) × weight × (0.85 if female) / (72 × Cr mg/dL). Dose = AUC × (GFR + 25)
Cockcroft-Gault is an estimate; a measured GFR is preferred at extremes of weight, age or muscle mass. Actual body weight is shown; some centres use adjusted weight above 120% of ideal.
Source: Cockcroft & Gault, Nephron 1976; Calvert et al., JCO 1989; FDA/NCI CTEP carboplatin dosing action letter, 2010 (GFR cap 125 mL/min)
Absolute neutrophil count
ANC = WBC × (neutrophils % + bands %) / 100
Grades: 1 below 2.0, 2 below 1.5, 3 below 1.0, 4 below 0.5 ×10⁹/L. Febrile neutropenia is ANC below 0.5 (or expected to fall) with a single temperature of 38.3 °C or 38.0 °C sustained over an hour.
Albumin-corrected calcium
mmol/L: Ca + 0.02 × (40 − albumin g/L). mg/dL: Ca + 0.8 × (4.0 − albumin g/dL)
Ionised calcium is more reliable when albumin is very low or pH is abnormal. Hypercalcaemia of malignancy is usually defined above 2.6 mmol/L (10.5 mg/dL) corrected.
RECIST 1.1 target-lesion response
PR: ≥30% decrease from baseline. PD: ≥20% increase from nadir and ≥5 mm absolute, or new lesions. CR: all target lesions gone
Sums of the longest diameters of up to five target lesions (two per organ); lymph nodes by short axis, counted as normal below 10 mm. Overall response also depends on non-target lesions.
Cumulative anthracycline dose
Doxorubicin equivalent = Σ dose × factor (epirubicin 0.8, daunorubicin 0.6, idarubicin 5, mitoxantrone 10.5)
ESC 2022 treats 250 mg/m² or more of doxorubicin-equivalent as a high-risk feature and 400 mg/m² or more as very high; risk is continuous and rises with chest radiotherapy, age and cardiac history.
Source: ESC 2022 cardio-oncology guideline (anthracycline equivalence)
Dose banding
Round to the nearest band; accept if |banded − exact| / exact ≤ tolerance
This is a generic rounding rule. National banding tables give agent-specific bands and vial combinations; use them where they exist.
Check before you prescribe
These tools reproduce published formulas and are tested against worked examples in the repository (src/lib/calculators.test.ts). They do not know the patient: renal and hepatic function, prior toxicity, protocol caps and local dose-banding tables all modify the answer. Confirm doses against the regimen source and your institution’s protocol. Not medical advice.